Copyright (C) 2005 Yanaihara Institute Inc. All Rights ReservedWe provide you more information about our antibodies
Summary Information of Antibodies (By Code Number)
Please click code number for reading antiserum data sheet if you need more
detail. (PDF file)
| Code | Antigen | Host | Immunohistochemistry | RIA ( final dilution) | Specificity | Quantity | Code |
| Y010 | VIP (Human, Porcine) | Rabbit | 1:1,000-4,000 | 1:21,000 | VIP(human,porcine) 100%, VIP(1-15) (human, porcine) 0%, secretin(porcine) 0%, GLP-1(7-37) 0%, GIP(1-30)(human) 0%,PACAP27 (human) 0%, PACAP38 (human) < 0.001%, GRF(human) 0% | 50 Κk | Y010 |
| Y020 | PHI (Human) | Rabbit | 1: 500-2,000 | 1:35,000 | PHI(human) 100%, PHI (porcine) 0.14%, PHI (13-27)(Human) 30%, PHI (20-27) (porcine) 0%, glucagon 0%, secretin (porcine) 0%, VIP (porcine) 0%, GRF (human) 0% | 50 Κk | Y020 |
| Y021 | PHI (13-27) (Human) | Rabbit | 1:1,000-4,000 | 1:70,000 | PHI (human) 100%, PHI (porcine) 0.08%, PHI (1-15) (human) 0%, PHI (13-27) (human) 100%, PHI (1-15) (porcine) 0%, PHI (14-27) (porcine) 0%, PHI (20-27) (porcine) 0%, glucagon 0%, secretin (porcine) 0%, VIP (porcine) 0%, GRF (human) 0% | 50 Κk | Y021 |
| Y022 | PHI (Rat) | Rabbit | 1:1,000-4,000 | 1:35,000 | PHI (rat) 100%, PHI (human) 80%, PHI (porcine) 75%, secretin (porcine) 0%, VIP (porcine) 0%, PACAP38 (human) 0% | 50 Κk | Y022 |
| Y030 | Secretin (Human) | Rabbit | 1:1,000-4,000 | 1:14,000 | Secretin (human) 100%, secretin (porcine) 92%, secretin (chicken) <0.01%, VIP (porcine) <0.01% | 50 Κk | Y030 |
| Y031 | Secretin (Porcine) | Rabbit | 1:1,000-4,000 | 1:54,000 | Secretin (porcine) 100%, secretin (4-27) (porcine) 60%, secretin (14-27)(porcine) 10%, secretin (18-27)(porcine) <0.01%, VIP (porcine) 0%, gastrin (human) 0%, glucagon 0% | 50 Κk | Y031 |
| Y032 | Secretin (Rat) | Rabbit | 1:1,000-4,000 | 1:56,000 | Secretin (rat) 100%, secretin (13-27) (rat) 90%, secretin (1-12) (rat) 0%, secretin (19-27) (rat) < 0.1%, prosecretin (1-41) (rat)< 0.1%, prosecretin (12-41) (rat) < 0.1%, GIP (1-30)-NH2(porcine) 0%, GLP-1 (7-36)-NH2 0%, glucagon 0%, PHI (rat) 0%, PACAP38 (human) 0%, VIP (porcine) 0% | 50 Κk | Y032 |
| Y040 | PACAP38 (Human) | Rabbit | 1:200-1,000 | 1:14,000 | PACAP38 (human) 100%, PACAP27 (human) 0%, VIP (porcine) 0%, PHI (rat) 0%, PHI (human) 0%, secretin (human) 0%, helodermin 0%, CCK-8 0%, met-enkephalin 0%, leu-enkaphalin 0%, dynorphin 0%, oxytocin 0%, vasopressin 0% | 50 Κk | Y040 |
| Y041 | PACAP38 (22-38) (Human) | Rabbit | 1:500-4,000 | 1:140,000 | PACAP38 (22-38) (human) 100%, PACAP38 (human) 30%, PACAP 38 (5-38) (human) 30%, PACAP38 (10-38) (human) 17.2%, PACAP38 (16-38) (human) 52%, PACAP27 (human) < 0.1%, glucagon 0%, VIP (porcine) 0%, PHI (human) 0%, secretin (human) 0% | 50 Κk | Y041 |
| Y042 | PACAP38 (1-15) (Human) | Rabbit | 1: 500-3,000 | 1:140,000 | PACAP38 (1-15) (human) 100%, PACAP27 (human) 30%, PACAP38 (human) 6.7%, VIP (porcine) 0%, PHI (rat) 0%, PHI (human) 0%, secretin (human) 0%, helodermin 0% | 50 Κk | Y042 |
| Y050 | PACAP27 (Human) | Rabbit | 1:1,000-4,000 | 1:280,000 | PACAP27 (human) 100%, PACAP38 (human) 0%, VIP (porcine) 0%, PHI (rat) 0%, PHI (human) 0%, secretin (human) 0%, helodermin 0% | 50 Κk | Y050 |
| Y051 | PACAP27 (13-27)(Human) | Rabbit | 1:1,000-6,000 | 1:140,000 | PACAP27 (13-27) (human) 100 %, PACAP27 (human) 149.9%, PACAP27 (8-27) (human) 112.9%, PACAP27 (16-27) (human) 54.9%, PACAP (22-27) (human) 3.3%, PACAP38 (human)<0.1%, PACAP38 (1-15) (human) 0%, VIP (porcine) 0%, glucagon 0%, PHI (human) 0%, secretin (human) 0% | 50 Κk | Y051 |
| Y060 | NPY (Human, Mouse, Rat) | Rabbit | 1:1,000-4,000 | 1:35,000 | NPY (human, mouse, rat) 100%, NPY (porcine) 100%, NPY (1-19) (human, mouse, rat) 0%, NPY (20-36) (human, mouse, rat) 25.6%, NPY (26-36) (human, mouse, rat) 0%, PYY (porcine) 100%, PP (human) 0%, PP (rat) 0% | 50 Κk | Y060 |
| Y061 | NPY (1-19)(Human, Mouse, Rat) | Rabbit | 1: 1,000-4,000 | 1:7,000 | NPY (1-19) (human, mouse, rat) 100%, NPY (human, mouse, rat) 10%, NPY (4-19) (human, mouse, rat) 100%, PYY (porcine) 0%, PP (human) 0% | 50 Κk | Y061 |
| Y070 | Peptide YY(PYY) (Porcine, Rat) | Rabbit | 1: 1,000- 4,000 | 1:14,000 | PYY ( porcine, rat ) 100%, PYY (1-19) (human) 0%, PYY (13-36) (human) 0.5%, PYY (19-36) (porcine, rat ) 0%, NPY (human) 0.7%, NPY (1-19) (human) 0%, NPY (20-36) (human) 0%, PP (human) 0% | 50 Κk | Y070 |
| Y072 | Peptide YY (PYY) (Human) | Rabbit | 1:1,000-9,000 | 1:70,000 | PYY (human) 100%, PYY (19-36)(human) <0.001%, PYY (1-19)(human) <0.001%, PYY (rat) 80%, PYY (13-36)(rat) <0.1%, PP (human) <0.001%, NPY (human) <0.001% | 50 Κk | Y072 |
| Y080 | Pancreatic Polypeptide (PP) (18-36)(Human) | Rabbit | 1: 1,000-4,000 | 1:56,000 | PP (18-36) (human) 100%, PP (human) 100%, NPY (human) 0%, PYY (human) 0% | 50 Κk | Y080 |
| Y090 | Pancreastatin (33-51) (Rat) | Rabbit | 1: 1,000-4,000 | 1:1,400,000 | Pancreastatin (33-51) (rat) 100%, pancreastatin (rat) 100%, chromogranin A (359- 389) (rat) 0% | 50 Κk | Y090 |
| Y100 | GIP (1-30)-OH(Porcine) | Rabbit | 1:1,000- 10,000 | 1:14,000 | GIP(1-30) (porcine) 100%, GIP (porcine) 0.9%, GIP (human) 0%, GIP(1-18) (porcine) 0%, secretin (porcine) 0%, VIP (porcine) 0%, PHI (porcine) 0%, GLP-1 (7-37) 0% | 50 Κk | Y100 |
| Y101 | GIP (Human) | Rabbit | 1:500-1,000 | 1:16,000 | GIP (human) 100%, GIP (15-30)-NH2(human) 25%,GIP (1-13) (human) 0%, GIP (31-42)(human) 0.9%, GIP (1-30)-NH2 (human) 110%, GIP (1-30)-OH (porcine) 1%, GIP (porcine) 1%, VIP (porcine) 0%, PHI (porcine) 0%, GLP-1 (7-36) (human) 0%, GLP-1 (7-36)-NH2(human) 0%, insulin (human) 0%, glucagon 0%, secretin (porcine) 0% | 50 Κk | Y101 |
| Y102 | GIP (Rat) | Rabbit | 1:5000-32,000 | 1:10000- | Based on non-competitive EIA: GIP (rat) 100%,GIP (18-42)(rat) 45%, Secretin (rat) 0%, VIP(porcine) 0%, GLP-1(7-36)-NH2< 4.5%, GLP-1(1-36)-NH2 < 3.8%,GLP-2(rat) 0%, Glucagon 0% | 50 Κk | Y102 |
| Y103 | GIP (18-42)(Rat) | Rabbit | 1:1000-5,000 | - | Based on non-competitive EIA: GIP (rat) >100%, GIP (18-42)(rat) 100%, Secretin (rat) 0%, VIP(porcine) 0%, GLP-1(7-36)-NH2 0%, GLP-1(1-36)-NH2 0%,GLP-2(rat) 0%, Glucagon 0% | 50 Κk | Y103 |
| Y110 | Gastrin34 (1-15) (Human) | Rabbit | 1: 500-2,000 | 1:45,000 | Gastrin34 (1-15) (human) 100%, gastrin34 (human) 43%, gastrin34 (1-5) (human) 30%, gastrin34 (6-15) (human) 0% | 50 Κk | Y110 |
| Y111 | Gastrin17 (G17) (Dog) | Rabbit | 1: 500- 2,000 | 1:10,500 | G17 (dog) 100%, G17 (human) 40% | 50 Κk | Y111 |
| Y120 | Motilin (Dog) | Rabbit | 1: 500-3,000 | 1:10,500 | Motilin (dog) 100%, motilin (human, porcine ) 20.8% | 50 Κk | Y120 |
| Y121 | Motilin (Human, Porcine) | Rabbit | 1:1,000-4,000 | 1:7,000 | Motilin (human, porcine) 100%, motilin (human, porcine) (7-22) 69.2%, motilin (human, porcine) (12-22) 115%, motilin (human, porcine)(1-6)Me 0.09% [15-Glutamine]-Motilin 96.7% | 50 Κk | Y121 |
| Y130 | Neurotensin | Rabbit | 1:1,000 | 1:10,500 | Neurotensin 100%, neurotensin (1-9) 21%, neurotensin (1-8) 16%, neurotensin (6-13) < 0.01%, neurotensin (9-12) 0% | 50 Κk | Y130 |
| Y140 | Met-Enkephalin-Arg6-Gly7-Leu8 | Rabbit | 1:1,000- 5,000 | 1:56,000 | Met-enkephalin-arg6-gly7-leu8 100%, phe4-met5-arg6-gly7-leu8 < 0.001%, met-enkephalin 0%, leu-enkephalin 0%, Ώ-endorphin 0%, ΐ-endorphin 0% | 50 Κk | Y140 |
| Y150 | Substance P | Rabbit | 1:1,000- 4,000 | 1:60,000 | substance P 100%, substance P (6-10) 20%, substance P (4-10) 0.5%, neurokinin A 1.0% | 50 Κk | Y150 |
| Y160 | GRP (Porcine) | Rabbit | 1:1,000-12,000 | 1:280,000 | GRP (porcine) 100%, GRP (14-27) (porcine) 261%, GRP (1-13) (porcine) 0%, bombesin 241%, substance P <0.001% | 50 Κk | Y160 |
| Y170 | Bombesin | Guinea Pig | 1:200-1,000 | 1:7,000 | Bombesin 100%, NΏ-glycyl-[Gln1]-bombesin 100%, NΏ-Tyr [Gln1]-bombesin 100%, des-14-amide-bombesin 25%, bombesin (4-14) 90%, bombesin (6-14) 90%, bombesin (8-14) 0%, ranatensin C 2.6%, GRP (porcine) < 0.001% | 50 Κk | Y170 |
| Y180 | Galanin (Porcine) | Rabbit | 1:500-2,000 | 1:17,500 | Galanin (porcine) 100%, galanin (3-29) (Porcine) 100%, galanin (10-29) (porcine) 100%, galanin (15-29) (porcine) 100%, GRP (porcine) 0%, neurokinin A 0%, neurokinin B 0%, neuromedin B 0%, substance P 0%, PP (human) 0%, glucagon 0%, VIP (porcine) 0% | 50 Κk | Y180 |
| Y182 | Galanin (1-15) | Rabbit | 1:500-2,000 | 1:10,500 | Galanin (1-15) 100%, galanin (rat) 100%, galanin (porcine) 100%, galanin (1-19) (porcine) 100%, galanin (2-29) (porcine) 53%, galanin (1-11) < 0.01%, PP (human) 0%, gastrin (human) 0%, NPY (human) 0%, PYY (porcine) 0% | 50 Κk | Y182 |
| Y183 | Galanin (15-29) (Rat) | Rabbit | 1:200-2,000 | 1:21,000 | Galanin (rat) 100%, galanin (15-29) (rat) 100%, galanin (human) 0% | 50 Κk | Y183 |
| Y184 | Galanin (9-30) (Human) | Rabbit | 1:500-2,000 | 1:21,000 | Galanin (human) 100%, galanin (9-30) (human) 66.4%, galanin (16-30) (human) 0%, galanin (rat) 6.8%, galanin (porcine) 3.6%, substance P 0%, neurokinin A 0% | 50 Κk | Y184 |
| Y185 | Preprogalanin (89-124) (Rat) | Rabbit | 1:500-2,000 | 1:21,000 | Preprogalanin (rat) 100%, preprogalanin (human) 80%, galanin (rat) 0% | 50 Κk | Y185 |
| Y186 |
Galanin (20-29) (Rat) | Rabbit | 1:500- 2,000 | Not Available | Based on non-competitiveEIA: Galanin (rat) 100%, Galanin (20-29) (rat) 100%, Galanin (human) 0% |
50 Κk | Y186 |
| Y190 | Preprorenin (21-64) (Human) | Rabbit | 1:200- 2,000 | 1:1,000-5,000 | Based on non-competitive EIA: Preprorenin(21-64) (human) 100%, prorenin(265-294) (human) 0%, prorenin(314-337) (human) 0%, prorenin (human, recombinant) 100%, renin (human, recombinant) 0% |
50 Κk | Y190 |
| Y191 | Preprorenin (265-294) (Human) Old name: Preprorenin (288-317) (Human) |
Rabbit | 1:1,000- 4,000 (frozen section) | 1:1,000-5,000 | Based on non-competitive EIA: Prorenin (265-294) (human) 100%, preprorenin (21-64) (human) 0.0%, prorenin (314-337) (human) <0.1%, prorenin (human, recombinant) 100%; may cross react to renin(human, recombinant). | 50 Κk | Y191 |
| Y192 | Preprorenin (314-337) (Human) | Rabbit | 1:1,000- 4,000 (frozen section) | 1:1,000-5,000 | Based on non-competitive EIA: Prorenin(314-337) (human) 100%, preprorenin(21-64) (human) 0.0%, prorenin(265-294) (human) <0.1%, prorenin (human, recombinant) 100%, renin (human, recombinant) 100% |
50 Κk | Y192 |
| Y201 | PTHrP (1-34)-NH2 | Rabbit | 1:500-1,000 | 1:21,000 | PTHrP (1-34)-NH2 100%, PTHrP (15-34)-NH2< 0.05%, PTHrP (1-19) 0%, PTHrP (7-34)-NH2 25% | 50 Κk | Y201 |
| Y202 | PTHrP (15-34)-NH2 | Rabbit | 1:200-1,000 | 1:7,000 | PTHrP (15-34)-NH2 100%, PTHrP (1-34)-NH2 70%, PTHrP (1-19) 0%, PTHrP (7-34)-NH2 25% | 50 Κk | Y202 |
| Y210 | CRF (24-41)(Human, Mouse, Rat) | Rabbit | 1:1,000-5,000 | 1:35,000 | CRF (24-41) (human, mouse, rat) 100%, CRF (human, mouse, rat) ~ 100% | 50 Κk | Y210 |
| Y211 | CRF (3-41)(Human, Mouse, Rat) | Rabbit | 1:1,000-5,000 | 1:7,000 | Based on ELISA: CRF (3-41) (human, mouse, rat) 100%, CRF (human, mouse, rat) 100%, CRF (17-41) (human, mouse, rat ) < 0.1%, urocortin (human) < 0.01%, urocortin (rat) < 0.01%, ACTH (human) < 0.01%, ACTH (mouse, rat) < 0.01% | 50 Κk | Y211 |
| Y220 | C-Peptide II (Rat) | Rabbit | 1:1,000-10,000 | 1:10,000 | C-peptide I (rat) 100%, C-peptide II (rat) 100%, C-peptide I (7-31) (rat) 100%, C-peptide II (7-31) (rat) 100%, C-peptide I (15-31) (rat) 100%, C-peptide II (15-31) (rat) 100%, C-peptide I (20-31) (rat) 80 %, C-peptide I (1-23) (rat) <0.001%, C-peptide II (1-23) (rat) <0.001%, C-peptide (human) 0.01% | 50 Κk | Y220 |
| Y221 | C-Peptide I (Rat) | Rabbit | 1:500-1,000 | RIA 1:10,500 EIA 1: 3,000 |
Based on EIA: C-peptide I (rat) 100%, C-peptide II (rat) 52.9%, C-peptide I (mouse) 28.8%, C-peptide II (mouse) 2.95%, C-peptide (human) 0% | 50 Κk | Y221 |
| Y222 | C-Peptide I (Mouse) | Rabbit | 1:1,000- 5,000 | - | Based on non-competitive EIA: C-Peptide I (mouse) 100%, C-Peptide II (mouse) 15.2%, C-Peptide I (rat) 20.9%, C-Peptide II (rat) 85%, C-Peptide (human) < 0.01%, C-Peptide (dog) < 0.01%, C-Peptide (porcine) < 0.1%, Glucagon < 0.01% |
50 Κk | Y222 |
| Y223 | C-Peptide II (Mouse) | Rabbit | 1:2,000- 10,000 | - | Based on non-competitive EIA: C-Peptide II (mouse) 100%, C-Peptide I (mouse) 5.2%, C-Peptide I (rat) 3.7%, C-Peptide II (rat) 72.3%, C-Peptide (human) < 1.5%, C-Peptide (dog) < 0.01%, Glucagon < 0.1%, C-peptide (porcine ) < 0.01% |
50 Κk | Y223 |
| Y230 | EGF (Human) | Rabbit | 1: 1,000-4,000 | 1:84,000 | EGF (human) 100%, EGF (rat) 0.006%, EGF (mouse) 0%, TGF-Ώ(human) 0%, IGF-1 (human) 0%, insulin (porcine) 0%, glucagon 0%, ACTH (human) 0%, PHI (human) 0% | 50 Κk | Y230 |
| Y231 | EGF (Rat) | Rabbit | 1: 1,000-4,000 | 1:140,000 | EGF (rat) 100%, EGF (human) 0.1%, EGF (mouse) 1.5%, TGF-Ώ (human) 0%, IGF-1 (human) 0%, insulin (porcine) 0%, glucagon 0% | 50 Κk | Y231 |
| Y240 | TGF-Ώ(Human) | Rabbit | 1: 200-500 | RIA 1: 5,440 EIA 1: 2,300 | Based on RIA: TGF-Ώ(human) 100%, EGF (human) 0%, EGF (rat) 0% | 50 Κk | Y240 |
| Y241 | TGF-ΐ1 (Human) | Rabbit | 1: 200-1,000 | 1:35,000 | TGF-ΐ1(human) 100%, EGF (human) 0%, EGF (rat) 0% | 50 Κk | Y241 |
| Y250 | basic FGF (Human) | Rabbit | 1: 500- 2,000 (frozen section) | 1:17,500 | basic FGF (human) 100%, basic FGF (bovine) 85%, TGF-Ώ(human) 0%, IL-1Ώ(human) 0%, IL-1ΐ(human) 0%, TGF-ΐ1 (human) 0% | 50 Κk | Y250 |
| Y251 | basic FGF (1-9) (Human) | Rabbit | 1: 200- 1,000 (frozen section) | 1:6,000 | Recombinant basic FGF (human) 100%, basic FGF (1-9)-Tyr (human) 100% | 50 Κk | Y251 |
| Y260 | acidic FGF (1-15) (Bovine) | Rabbit | 1:200-1,000 (frozen section) | 1:7,000 | acidic-FGF (1-15) (Bovine) 100%, Recombinant basic-FGF (human) 0%, Recognize acidic-FGF (bovine, rat, human) | 50 Κk | Y260 |
| Y280 | Retinoblastoma (RB ) Protein (901-928) (Human) | Rabbit | 1:200-1,000 (frozen section) | 1:10,500 | RB protein (901-928) (human) 100%. Recognizes 110kDa protein in rat liver extract by immunoblot analysis. | 50 Κk | Y280 |
| Y290 | Chromogranin A (359-389) (Rat) | Rabbit | 1:1,000 | 1:14,000 | Chromogranin A (359-389) (rat) 100%, pancreastatin (rat) 0% | 50 Κk | Y290 |
| Y291 | Chromogranin A (94-130) (Rat) | Rabbit | 1:1,000 | 1:7,000 | Chromogranin A (94-130) (rat) 100%, Pancreastatin (rat) 0%. Recognizes Chromogranin A (rat) and ΐ-granin. | 50 Κk | Y291 |
| Y292 | Chromogranin A (343-360) (Rat) | Rabbit | 1:1,000 | 1:7,000 | Chromogranin A (343-360) (rat) 100%, Pancreastatin (rat) 0% | 50 Κk | Y292 |
| Y293 | Chromogranin A (344-374) (Human) | Rabbit | 1:1,000 | RIA 1:3,500-8,400 EIA 1: 2,500 | Based on RIA: CgA (344-374) (human) 100%, CgA (359-389) (rat) 33.5%, CgA (375-389)(rat) 0%, CgA (360-374)(human) 0% | 50 Κk | Y293 |
| Y294 | Chromogranin A (1-28) (Rat) | Rabbit | 1:500- 3,000 (frozen section) | RIA 1:21,000 | Based on RIA: Chromogranin A (1-28) (rat) 100%, Pancreastatin (rat) 0%. |
50 Κk | Y294 |
| Y300 | Ώ-Endorphin | Rabbit | 1:200-1,000 (frozen section) | 1:14,000 | Ώ-Endorphin 100%, ΐ-endorphin 7%, Α-endorphin 34%, met-enkephalin 0%, leu-enkephalin 0% | 50 Κk | Y300 |
| Y310 | Pro-LH-RH (1-26) (Human) | Rabbit | 1:500-5,000 (frozen section) | 1:7,000 | Pro-LH-RH (1-26) (human) 100%, GAP (1-56) (human) 0.15%, GAP (34-56) (human) 0%, LH-RH 0% | 50 Κk | Y310 |
| Y311 | Gonadotropin-Releasing Hormone-Associated Peptide(GAP) (34-56) (Human) | Rabbit | 1:500-4,000 (frozen section) | 1:4,900 | GAP (34-56) (human) 100%, GAP (1-56) (human) 100%, GAP (15-56) (human) 100%, GAP (25-56)(human) 100%, GAP (41-56)(human) 0.5%, leumorphin (human) 0%, LH-RH 0%, somatostatin 0% | 50 Κk | Y311 |
| Y312 | Gonadotropin-Releasing Hormone-Associated Peptide(GAP) (28-56) (Rat) | Rabbit | 1:500-4,000 (frozen section) | 1:70,000 | GAP (28-56) (rat) 100%, GAP (34-56) (rat) 100%, GAP (rat) 100%, GAP (25-56) (human) <0.001%, LH-RH 0% | 50 Κk | Y312 |
| Y320 | GLP-1 (7-36)-NH2 | Rabbit | 1:1000-4,000 | RIA 1:21,000 EIA 1:8,000 |
Base on EIA: GLP-1 (7-36)-NH2 100%, GLP-1(1-37)-OH<0.01%, GLP-1(7-37)-OH<0.01%, GLP-1(1-36)-NH2 0.31%, GLP-2 (rat) < 0.1%, GLP-2 (human) < 0.1%, glicentin (human) < 0.1%, glucagon < 0.1% | 50 Κk | Y320 |
| Y321 | GLP-2 (14-33)(Rat) | Rabbit | 1:1,000-5,000 | 1:10,500 | GLP-2 (14-33) (rat) 100%, GLP-2 (rat) 100%, GLP-1 (7-36)-NH2(rat) 0%, glucagon 0% | 50 Κk | Y321 |
| Y322 | GLP-2 (Rat) | Rabbit | 1:500-2,000 | EIA 1:3,000-50,000 |
Base on EIA: GLP-2 (rat) 100%, GLP-2 (human) 100%, GLP-2 (3-33) (rat) 90%, GLP-2 (14-33) (rat) 36%, GLP-2 (1-18) (rat) < 0.1%, GLP-1(7-36)-NH2(rat) 0%, glucagon 0%, glicentin (rat) 0% | 50 Κk | Y322 |
| Y323 | GLP-2 (Mouse) | Rabbit | 1:1,000- 5,000 | EIA 1:10,000-60,000 | Based on competitive EIA: GLP-2 (mouse) 100%, GLP-2 (rat) 100%, GLP-2 (14-33) (rat) 117.4%, GLP-2 (human) 44.7%, GLP-2 (1-18) (rat) 0%, GLP-1 (7-36)-NH2 0% |
50 Κk | Y323 |
| Y324 | Glicentin (1-32) (Rat) | Rabbit | 1:1,000- 5,000 | EIA 1:5,000-25,000 |
Based on competitive EIA: Glicentin (1-32) (rat) 100%, Glicentin (rat) 100%, Glicentin (human) 0.2%, Glucagon < 0.1%, GLP-1 < 0.1% , GLP-2 (rat) < 0.1% |
50 Κk | Y324 |
| Y330 | Atrial Natriuretic Peptide(ANP) (Mouse, Rat) | Rabbit | 1:1,000-4,000 | 1:42,000 | ANP (mouse, rat) 100%, ANP (human) 80% | 50 Κk | Y330 |
| Y340 | Calcitonin Gene-Related peptide (Ώ-CGRP) (Mouse, Rat) | Rabbit | 1:1,000-5,000 | 1:42,000 | Ώ-CGRP (mouse, rat) 100% | 50 Κk | Y340 |
| Y350 | ACTH (Mouse, Rat) | Rabbit | 1:1,000-4,000 | - | Based on non-competitive EIA: ACTH (mouse, rat) 100%, ACTH (human) 80% | 50 Κk | Y350 |
| Y351 | ACTH (21-39)(Mouse, Rat) | Rabbit | 1:1,000-4,000 | 1:7,000 | ACTH (21-39) (Mouse, rat) 100%, ACTH (mouse, rat) 100% | 50 Κk | Y351 |
| Y352 | ACTH (1-23)(Mouse, Rat) | Rabbit | 1:200-1,000 | 1:10,500 | ACTH (1-23) (mouse, rat) 100%, ACTH (mouse, rat) 100% | 50 Κk | Y352 |
| Y360 | Urocortin (3-40)(Mouse, Rat) | Rabbit | 1:1,000-5,000 | 1:10,500 | Urocortin (3-40) (mouse, rat)100%, urocortin (mouse, rat) 164.7%, urocortin (human) ~100%, urocortin (30-40) (mouse, rat) 100%, urocortin (7-40) (mouse, rat) 260%, urocortin (1-22) (mouse, rat) < 0.1%, CRF (human, mouse rat ) < 0%, urotensin I (carp) < 0.1% | 50 Κk | Y360 |
| Y361 | Urocortin (Mouse, Rat) | Rabbit | 1:1,000-6,000 | 1:16,000 | Urocortin (mouse, rat) 100%, urocortin (human) ~100%, urocortin (1-22) (mouse, rat) < 0.5%, urocortin (23-40) (mouse, rat) 45%, CRF (human,mouse, rat) < 0%, urotensin I (carp) 2% | 50 Κk | Y361 |
| Y362 | Urocortin 1 (Mouse, Rat) | Rabbit | 1 :5,000 | EIA 1:8,000 | Based on EIA: Urocortin 1 (mouse,@rat) 100%, urocortin 1 (8-40) (mouse, rat) 100%, urocortin 1 (16-40) (mouse, rat) 84.67%, urocortin 1 (23-40) (mouse, rat) 96.82%, urocortin 1 (30-40) (mouse, rat) 16.47%, urocortin 1 (1-14) (mouse, rat) 0.14%, urocortin 1 (human) 51.32%, urocortin 2 (mouse) 0%, urocortin 2 (rat) 0%, urocortin 3 (mouse) 0%, ACTH (human) 0%, ACTH (mouse, rat) 0%, CRF (human, mouse, rat) 0%, CRF (17-41) (human, mouse, rat) 0% | 50 Κk | Y362 |
| Y363 | Urocortin 2 (Mouse) | Rabbit | 1 :5,000 | EIA 1:8,000 | Based on EIA: Urocortin 2 (mouse) 100%, urocortin 2 (7-38) (mouse) 80.52 %, urocortin 2 (14-38) (mouse) 24.23%, urocortin 2 (21-38) (mouse) 0.21%, urocortin 2 (26-38) (mouse) 0.41%, urocortin 2 (32-38) (mouse) 0.19%, urocortin 2 (1-13) (mouse) 0.12%, urocortin 1 (mouse, rat) 0%, urocortin 1 (human) 0%, urocortin 2 (rat) < 1%, urocortin 3 (mouse) 0%, ACTH (human) 0%, ACTH (mouse, rat) 0.61%, CRF (human, mouse, rat) 0%, CRF (17-41) (human, mouse, rat) 0% | 50 Κk | Y363 |
| Y364 | Urocortin 3 (Mouse) | Rabbit | 1 :5,000 | EIA 1:8,000 | Based on EIA: Urocortin 3 (mouse) 100%, urocortin 3 (7-38) (mouse) 78.72%, urocortin 3 (13-38) (mouse) 80.79%, Urocortin 3 (21-38) (mouse) 57.89%, urocortin 3 (28-38) (mouse) 47.58%, urocortin 3 (32-38) (mouse) 72.26%, urocortin 3 (1-12) (mouse) 0.15%, urocortin 1 (mouse, rat) 0%, urocortin 1 (human) 0.04%, urocortin 2 (mouse) 0%, urocortin 2 (rat) 0%, ACTH (human) 0.03%, ACTH (mouse, rat) 0.03%, CRF (human, mouse, rat) 0.01%, CRF (17-41) (human, mouse, rat) 0% | 50 Κk | Y364 |
| Y365 | Urocortin 2 (Rat) | Rabbit | 1 : 400 | EIA 1:16,000 | Urocortin 2 (rat) 100%, urocortin (mouse) 94%, urocortin 1 (mouse, rat) 0%, urocortin 3 (mouse) 0%, CRF (1-41) (human, mouse ,rat) 0% | 50 Κk | Y365 |
| Y370 | Insulin (Human) | Guinea Pig | 1:1,000-5,000 | 1:21,000 | Base on ELISA: Insulin (human) 100%, insulin (porcine) 100%, insulin (rabbit) 100%, insulin (dog) 100%, insulin (bovine) 18%, proinsulin (human) 20% | 50 Κk | Y370 |
| Y380 | Luminal Cholecystokinin-Releasing Factor (LCRF) (Rat) | Rabbit | 1:500-2,000 | 1:10,500 | LCRF (rat) 100%, LCRF (1-21) 10%, LCRF (19-41) 0.01% | 50 Κk | Y380 |
| Y390 | GRF/GH-RH (Rat) | Rabbit | 1:1,000-4,000 | 1:21,000 | GRF/GH-RH 100%, not tested for other peptide hormones | 50 Κk | Y390 |
| Y400 | Na+Channel II (467-485) (Rat) | Rabbit | 1:1,000-4,000 (frozen section) | - | This antiserum recognizes sodium channel II, not tested for other types of ion channels | 50 Κk | Y400 |
| Y410 | Angiostatin (128-141) (Mouse) | Rabbit | 1 :100-500 (frozen section) 1:50-500 for Western blotting |
- | Angiostatin (128-141) (mouse) 100%, by Western blotting, a 38-kDa band corresponding to mouse angiostatin was observed in serum of mice bearing s.c. tumors . | 50 Κk | Y410 |
| Y411 | Angiostatin (285-294) (Mouse) | Rabbit | 1 :100-500(frozen section) | - | Angiostatin (285-294) (mouse) 100% | 50 Κk | Y411 |
| Y420 | PTH (1-34)-NH2 (Rat) | Rabbit | 1:1,000-4,000 | 1:21,000 | PTH (1-34)-NH2(rat) 100%, PTH (1-34)-NH2(human) 1%, PTHrP (1-34)-NH2(human) 0% | 50 Κk | Y420 |
| Y421 | PTH (1-15)(Mouse, Rat) | Rabbit | 1:1,000-4,000 | 1:21,000 | PTH (1-15) (mouse, rat) 100%, PTH (1-34)-NH2 (mouse, rat) 10% | 50 Κk | Y421 |
| Y430 | Nociceptin/Orphanin FQ | Rabbit | 1:500-1,000 (frozen section) | 1:10,500 | Nociceptin 100%, dynorphin A 0%, ΐ-endorphin 0% | 50 Κk | Y430 |
| Y440 | Humanin | Rabbit | 1 :5,000 | EIA 1:8,000 | Based on EIA: Humanin (5-24) 35%, humanin (9-24) 1.9%, humanin (14-24) 0.18%, humanin (19-24) 0.18%, humanin (9-18) 0%, rattin-38 0%, rattin-24 0% | 50 Κk | Y440 |
| Y441 | Rattin-24 | Rabbit | 1 :20,000 | EIA 1:10,000 | Based on EIA: Rattin-24 100%, rattin-38 100%, humanin 3.8% | 50 Κk | Y441 |
| Y450 | Orexin A | Rabbit | 1 : 10,000 | EIA 1:8,000 | Based on EIA: Orexin A (bovine, dog, human, mouse, porcine, rat) 100%, Orexin B (mouse, rat) 0 % | 50 Κk | Y450 |
| Y451 | Orexin B (Mouse, Rat) | Rabbit | 1 : 6,000 | EIA 1:8,000 | Based on EIA: Orexin B (mouse, rat) 100%, Orexin A (bovine, dog, human, mouse, porcine, rat) 0 % | 50 Κk | Y451 |
| Y460 | Obestatin (Mouse, Rat) | Rabbit | 1 : 5,000 | EIA 1:27,000 |
Based on non-competitive EIA:Obestatin (mouse, rat) 100%, Obestatin (11-23) (mouse, rat) 90.42%, Obestatin
(1-10)(mouse, rat, human) 25.95%, Obestatin (1-23)-OH (mouse, rat) 20.76%,
Obestatin (human) 26.37%, Obestatin (human) (11-23) 24.91%, Ghrelin (mouse,
rat) 0%, Des-octanonyl ghrelin (mouse, rat) 0% |
50 Κk | Y460 |
| Y461 | Obestatin (Human) | Rabbit | 1 : 5,000 | - | Based on non-competitive EIA:Obestatin (human) 100% | 50 Κk | Y461 |
| Y470 | Carassius RFamide | Rabbit | 1 : 1000-5,000 | - | Based on non-competitive EIA: Carassius RFamide100% PrRP(12-31)-NH2(PrRP20)(rat) 100%, PrRP(12-31)-NH2 (PrRP20)(human) 27.3%, PrRP(3-31)-NH2(rat) 41.2%, PrRP(3-31)-NH2(human) 22.5% |
50 Κk | Y470 |
| Y480 | PSA (53-92) (Human) | Rabbit | 1 : 5,000 | EIA : 1:1000-4,000 | PSA(53-92)(human) 100%, PSA (42-92 )(human) 100%,PSA(human) 100% | 50 Κk | Y480 |
| YA010 | Amyloid ΐProtein (1-40) (Human) | Rabbit | 1:1,000 | - | Based on non-competitive EIA: Amyloid ΐprotein (human) specific | 50 Κk | YA010 |
| YC010 | IL-1 Ώ(Rat) | Rabbit | Western blotting 1:1,000 | ELISA 1:10,000 |
IL-1Ώ(rat) 100%, IL-1Ώ(human) 24.8%, IL-1ΐ(rat) <0.01%, IL-1ΐ(human) <0.01%, TNF-Ώ(rat) <0.01%, TNF-Ώ(human) <0.01%, other cytokines <0.01% | 50 Κk | YC010 |
| YC011 | IL-1 Ώ(Rat) | Goat | Western blotting 1:1,000 | ELISA 1:1,000 | IL-1Ώ(rat) 100%, IL-1Ώ(human) 5.9%, IL-1ΐ(rat) <0.5%, IL-1ΐ(human) <0.5%, TNF-a(rat) <0.5%, TNF-Ώ(human) <0.5%, other cytokines <0.5% | 50 Κk | YC011 |
| YC020 | IL-1 ΐ(Rat) | Rabbit | Western blotting 1:1,000 | ELISA 1:1,000 | IL-1ΐ(rat) 100%, IL-1ΐ(human) 6.8%, IL-1Ώ(rat) <0.1%, IL-1Ώ(human) <0.1%, TNF-Ώ(rat) <0.1%, TNF-Ώ(human) <0.1%, other cytokines <0.1% | 50 Κk | YC020 |
| YC021 | IL-1 ΐ(Rat) | Goat | Western blotting 1:1,000 | ELISA 1:1,000 | IL-1ΐ(rat) 100%, IL-1ΐ(human) 19.2%, IL-1Ώ(rat) <0.01%, IL-1Ώ(human) <0.01%, TNF-Ώ(rat) <0.01%, TNF-Ώ(human) <0.01%, other cytokines <0.01% | 50 Κk | YC021 |
| YC022 | IL-1 ΐ(Rat) | Monoclonal | Western blotting 1:1,000 | ELISA 1:20,000 |
IL-1ΐ(rat) 100%, IL-1ΐ(human) <0.28%, IL-1Ώ(rat) <0.01%, IL-1Ώ(human) <0.01%, TNF-Ώ(rat) <0.01%, TNF-Ώ(human) <0.01%, other cytokines <0.01% | 50 Κk | YC022 |
| YC030 | TNF-Ώ(Rat) | Rabbit | Western blotting 1:1,000 | ELISA 1:10,000 |
TNF-Ώ(rat) 100%, TNF-Ώ(human) 26.2%, IL-1Ώ(rat) <0.01%, IL-1Ώ(human) < 0.01%, IL-1ΐ(rat) <0.01%, IL-1ΐ(human) <0.01%, other cytokines <0.01% | 50 Κk | YC030 |
| YC031 | TNF-Ώ(Rat) | Goat | Western blotting 1:1,000 | ELISA 1:1,000 | TNF-Ώ(rat) 100%, TNF-Ώ(human) 35.7%, IL-1Ώ(rat) <0.01%, IL-1Ώ(human) < 0.01%, IL-1ΐ(rat) <0.01%, IL-1ΐ(human) <0.01%, other cytokines <0.01% | 50 Κk | YC031 |
| YC032 | TNF-Ώ(Rat) | Monoclonal | Western blotting 1:1,000 | ELISA 1:1,000 | TNF-Ώ(rat) 100%, TNF-Ώ(human) <0.05%, IL-1Ώ(rat) <0.05%, IL-1Ώ(human) < 0.05%, IL-1ΐ(rat) <0.05%, IL-1ΐ(human) <0.05%, other cytokines <0.05% | 50 Κk | YC032 |
| YC040 | Leptin (Rat) | Rabbit | 1:4,000 | 1:21,000 | Leptin(rat) 100%, leptin(human) 10% | 50 Κk | YC040 |
| YM010 |
2,3,7,8-Tetrachlorodibenzo-p-dioxin | Mouse | Not Available | EIA possible | 2,3,7,8-Tetrachlorodibenzo-p-dioxin 100% 2,3,7-Trichlorodibenzo-p-dioxin 15% 1,2,3,7,8-Pentachlorodibenzo-p-dioxin 0.6% 1,2,3,4,6,7,8,9-Octachlorodibenzo-p-dioxin <@0.10% |
1mg | YM010 |
| 2,3,4,7,8-Pentachlorodibenzofuran @14.80% 1,2,3,4,6,7,8,9-Octachlorodibenzofuran@<0.01% |
|||||||
| 3,3',4,4',5-Pentachlorobiphenyl @0.50% 2,3',4,4',5-Pentachlorobiphenyl <0.10% |
|||||||
| YP010 | LH-RH | Rabbit | 1:500-4,000 (frozen section) | 1:60,000 | LH-RH 100%, LH-RH (4-10) 100%, LH-RH-OH < 0.001%, LH-RH (2-8) < 0.001%, angiotensin-I 0%, neurotensin 0%, oxytocin 0%, substance P 0%, somatostatin 0%, TRH 0%, vasopressin 0% | 50 Κk | YP010 |
| YP020 | Somatostatin | Rabbit | 1:500-4,000 (frozen section) | 1:60,000 | Somatostatin-14 100%, [Arg1] somatostatin-14 20%, [Ser3, Ser14] somatostatin-14 < 0.001% | 50 Κk | YP020 |
| YP030 | CCK-8 | Rabbit | 1:200-1,000 | 1:5,000 | CCK-8 100%, CCK-33 100%, CCK-39 84.6%, CCK-8 (nonsulfated ) <0.01%, CCK-4 <0.01%, gastrin 17-I <0.01%, caerulein <0.01% | 50 Κk | YP030 |
| YP040 | Total Glucagon | Rabbit | 1:1,000-5,000 (frozen section) | 1:80,000 | Pancreatic glucagon 100%, glicentin (porcine) 100%, glucagon (1-12) < 0.001%, glucagon (13-17) <0.001%, glucagon (19-29) 0%, secretin (porcine) 0%, VIP (porcine) 0% | 50 Κk | YP040 |
| YP050 | NO Synthase I (998-1024) (Human) | Rabbit | 1:1,000-4,000 (frozen section) Immunoblotting 1: 2,000 | RIA 1:14,000 EIA 1: 9,000 | Base on RIA: NO Synthase I (998-1024) (human) 100%, NO Synthase II (human) 0%, NO Synthase III (rat) 0% | 50 Κk | YP050 |
| YP051 | NO Synthase II (77-105) (Rat) | Rabbit | 1:1,000 (frozen section) | - | Based on non-competitive EIA: NO Synthase II (rat) 100%, NO Synthase II (mouse) 70%, NO Synthase I (rat) 0%, NO Synthase III (rat) 0% | 50 Κk | YP051 |
| YP060 | ATP Receptor: P2X4 (370-388) (Rat) | Rabbit | 1:5,000 (frozen section) | - | P2X4 (rat), not tested for other P2X subtypes | 50 Κk | YP060 |
| YP070 | G-Protein: GΏ olf (23-38) (Human, Mouse, Rat) | Rabbit | Immunoblotting 1:1,000 | - | Specificity (based on western blotting): Ga olf specific | 50 Κk | YP070 |
| YP071 | G-Protein: GΏ i3 (105-127) (Human) | Rabbit | Immunoblotting 1:1,000 | - | Specificity (based on western blotting): Ga i3 specific | 50 Κk | YP071 |
| YP080 | S100ΐ(41-60)(Human, Mouse, Rat) | Rabbit | 1:1,000-10,000 | - | Based on non-competitive EIA: S100ΐ(41-60) (human,mouse,rat) 100%, S100ΐ(16-36)(Human, mouse, rat) < 0.1%, S100ΐ(74-92) (human, mouse)@< 0.1% |
50 Κk | YP080 |
| YP081 | S100ΐ(74-92)(Human, Mouse) | Rabbit | 1:1,000- 10,000 | - | Based on non-competitive EIA: S100ΐ(74-92) (human, mouse) 100%, S100ΐ(16-36)(Human, mouse, rat) < 0.1%, S100ΐ(41-60) (human, mouse, rat) < 0.1% |
50 Κk | YP081 |
@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@Top